SEWA S. LEGHA, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
To the editor: The recent article by Kiang and Kennedy (Ann Intern Med 87:687-690, 1977) adds to the growing literature on the effectiveness and relative lack of toxicity from tamoxifen (1-3). Evidence is now sufficient to claim that antitumor activity of tamoxifen in metastatic breast cancer in postmenopausal women is at least equal to that of conventionally used estrogens. Because of its excellent patient tolerance, tamoxifen's use is justified in preference to diethylstilbestrol as the primary therapy of recurrent breast cancer in postmenopausal patients. Further, Kiang and Kennedy's paper corroborates previous reports with other antiestrogens such as nafoxidine (4) that
LEGHA SS. Tamoxifen for Breast Cancer. Ann Intern Med. ;88:574. doi: 10.7326/0003-4819-88-4-574_1
Download citation file:
Published: Ann Intern Med. 1978;88(4):574.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use